Home Cart Sign in  
Chemical Structure| 210421-74-2 Chemical Structure| 210421-74-2

Structure of Sitaxsentan sodium
CAS No.: 210421-74-2

Chemical Structure| 210421-74-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Sitaxsentan sodium has selectory antagonism of endothelin A (ETA) receptor with the IC50 and Ki value of 1.4 nM and 0.43 nM respectively.

Synonyms: TBC11251 sodium; IPI 1040 sodium; Thelin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Sitaxsentan sodium

CAS No. :210421-74-2
Formula : C18H14ClN2NaO6S2
M.W : 476.89
SMILES Code : O=S([N-]C1=C(Cl)C(C)=NO1)(C2=C(C(CC3=C(C)C=C(OCO4)C4=C3)=O)SC=C2)=O.[Na+]
Synonyms :
TBC11251 sodium; IPI 1040 sodium; Thelin
MDL No. :MFCD11040990
InChI Key :MDTNUYUCUYPIHE-UHFFFAOYSA-N
Pubchem ID :11477084

Safety of Sitaxsentan sodium

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Sitaxsentan sodium

GPCR

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00593905 - Unknown July 2013 United States, Pennsylvania ... More >> Allegheny General Hospital Recruiting Pittsburgh, Pennsylvania, United States, 15212 Contact: Andrea L Nowicki, BA    412-359-3653    anowicki@wpahs.org    Contact: Raymond L Benza, MD    412.359.3584    rbenza@wpahs.org    Principal Investigator: Raymond L Benza, MD Less <<
NCT00810732 Chronic Kidney Disease ... More >> CRD Less << Phase 2 Completed - United Kingdom ... More >> Pfizer Investigational Site Edinburgh, Scotland, United Kingdom, EH4 2XU Less <<
NCT00796666 Pulmonary Arterial Hypertensio... More >>n Pulmonary Hypertension Less << Phase 3 Terminated(Safety Issue The tr... More >>ial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.) Less << - -
NCT00796666 - Terminated(Safety Issue The tr... More >>ial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.) Less << - -
NCT00795639 Pulmonary Arterial Hypertensio... More >>n Pulmonary Hypertension Less << Phase 3 Terminated(Safety Issue The tr... More >>ial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.) Less << - -
NCT00796510 - Terminated(Safety Issue The tr... More >>ial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury) Less << - -
NCT00981968 Healthy Phase 1 Completed - United States, California ... More >> Pfizer Investigational Site Glendale, California, United States, 91206 Less <<
NCT00796510 Pulmonary Arterial Hypertensio... More >>n Pulmonary Hypertension Less << Phase 3 Terminated(Safety Issue The tr... More >>ial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury) Less << - United States, California ... More >> Pfizer Investigational Site Fountain Valley, California, United States, 92708 Romania Pfizer Investigational Site Cluj Napoca, Romania, 400 001 Ukraine Pfizer Investigational Site Kyiv, Ukraine Less <<
NCT00744211 - Completed - -
NCT00995566 - Terminated(The trial was prema... More >>turely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.") Less << - Belgium ... More >> Pfizer Investigational Site Bruxelles, Belgium, 1070 Pfizer Investigational Site Leuven, Belgium, 3000 France Pfizer Investigational Site Nice, France, 06000 Germany Pfizer Investigational Site Hannover, Germany, 30625 Less <<
NCT00995566 - Terminated(The trial was prema... More >>turely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.") Less << - -
NCT00811018 Pulmonary Arterial Hypertensio... More >>n Less << Phase 3 Terminated(This trial was prem... More >>aturely terminated on Dec 9 2010 due to safety concerns, specifically emerging evidence of hepatic injury.) Less << - -
NCT00795639 - Terminated(Safety Issue The tr... More >>ial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.) Less << - -
NCT00034307 Pulmonary Hypertension Phase 2 Phase 3 Unknown - -
NCT00811018 - Terminated(This trial was prem... More >>aturely terminated on Dec 9 2010 due to safety concerns, specifically emerging evidence of hepatic injury.) Less << - -
NCT01204853 Hypertension, Pulmonary Phase 3 Terminated(Safety Issue The tr... More >>ial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.) Less << - Japan ... More >> Pfizer Investigational Site Nagoya, Aichi, Japan Pfizer Investigational Site Shinjyuku-ku, Tokyo, Japan Less <<
NCT01210443 - Terminated(Safety Issue The tr... More >>ial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.) Less << - -
NCT00744211 Heart Disease Not Applicable Completed - United States, South Carolina ... More >> Ralph H. Johnson VA Medical Center, Charleston, SC Charleston, South Carolina, United States, 29401-5799 Less <<
NCT01204853 - Terminated(Safety Issue The tr... More >>ial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.) Less << - -
NCT01445873 - Completed - -
NCT01445873 - Completed - -
NCT00080457 Pulmonary Hypertension Phase 3 Completed - United States, Texas ... More >> Encysive Pharmaceuticals Houston, Texas, United States, 77401 Less <<
NCT01210443 Hypertension, Pulmonary Phase 3 Terminated(Safety Issue The tr... More >>ial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.) Less << - Japan ... More >> Pfizer Investigational Site Nagoya, Aichi, Japan Pfizer Investigational Site Shinjyuku-ku, Tokyo, Japan Less <<
NCT00303498 Diastolic Heart Failure Phase 2 Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.10mL

0.42mL

0.21mL

10.48mL

2.10mL

1.05mL

20.97mL

4.19mL

2.10mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories